The use of proteomics in identifying differentially expressed serum proteins in humans with type 2 diabetes

<p>Abstract</p> <p>Background</p> <p>The aim of the study was to optimize protocols for finding and identifying serum proteins that are differentially expressed in persons with normal glucose tolerance (NGT) compared to individuals with type 2 diabetes mellitus (T2DM).&...

Full description

Bibliographic Details
Main Authors: Göransson Michael, Eberhardson Michael, Sundsten Tea, Bergsten Peter
Format: Article
Language:English
Published: BMC 2006-12-01
Series:Proteome Science
Online Access:http://www.proteomesci.com/content/4/1/22
id doaj-cff88319ca64477499ecd17e47c09efc
record_format Article
spelling doaj-cff88319ca64477499ecd17e47c09efc2020-11-25T01:05:30ZengBMCProteome Science1477-59562006-12-01412210.1186/1477-5956-4-22The use of proteomics in identifying differentially expressed serum proteins in humans with type 2 diabetesGöransson MichaelEberhardson MichaelSundsten TeaBergsten Peter<p>Abstract</p> <p>Background</p> <p>The aim of the study was to optimize protocols for finding and identifying serum proteins that are differentially expressed in persons with normal glucose tolerance (NGT) compared to individuals with type 2 diabetes mellitus (T2DM).</p> <p>Serum from persons with NGT and persons with T2DM was profiled using ProteinChip arrays and time-of-flight mass spectra were generated by surface enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS).</p> <p>Results</p> <p>Mass spectra from NGT- and T2DM-groups were compared. Fifteen proteins ranging from 5 to 79 kDa were differentially expressed (p < 0.05). Five of these proteins showed decreased and ten showed increased serum levels in individuals with T2DM. To be able to identify the proteins, the complexity of the sample was reduced by fractionation approaches. Subsequently, the purified fractions containing biomarkers were separated by one-dimensional SDS-polyacrylamide gel electrophoresis (SDS-PAGE) in two identical lanes. Protein bands of the first lane were excised and subjected to passive elution to recapture the biomarkers on ProteinChip arrays. The corresponding bands of the second lane were subjected to peptide-mass fingerprinting (PMF). Using this approach four of the differentially expressed proteins were identified as apolipoprotein C3 (9.4 kDa), transthyretin (13.9 kDa), albumin (66 kDa) and transferrin (79 kDa). Whereas apolipoprotein C3 and transthyretin were up-regulated, albumin and transferrin were down-regulated in T2DM.</p> <p>Conclusion</p> <p>Protocols for protein profiling by SELDI-TOF MS and protein identification by fractionation, SDS-PAGE and PMF were optimized for serum from humans with T2DM. With these protocols differentially expressed proteins were discovered and identified when serum from NGT- and T2DM-individuals was analyzed.</p> http://www.proteomesci.com/content/4/1/22
collection DOAJ
language English
format Article
sources DOAJ
author Göransson Michael
Eberhardson Michael
Sundsten Tea
Bergsten Peter
spellingShingle Göransson Michael
Eberhardson Michael
Sundsten Tea
Bergsten Peter
The use of proteomics in identifying differentially expressed serum proteins in humans with type 2 diabetes
Proteome Science
author_facet Göransson Michael
Eberhardson Michael
Sundsten Tea
Bergsten Peter
author_sort Göransson Michael
title The use of proteomics in identifying differentially expressed serum proteins in humans with type 2 diabetes
title_short The use of proteomics in identifying differentially expressed serum proteins in humans with type 2 diabetes
title_full The use of proteomics in identifying differentially expressed serum proteins in humans with type 2 diabetes
title_fullStr The use of proteomics in identifying differentially expressed serum proteins in humans with type 2 diabetes
title_full_unstemmed The use of proteomics in identifying differentially expressed serum proteins in humans with type 2 diabetes
title_sort use of proteomics in identifying differentially expressed serum proteins in humans with type 2 diabetes
publisher BMC
series Proteome Science
issn 1477-5956
publishDate 2006-12-01
description <p>Abstract</p> <p>Background</p> <p>The aim of the study was to optimize protocols for finding and identifying serum proteins that are differentially expressed in persons with normal glucose tolerance (NGT) compared to individuals with type 2 diabetes mellitus (T2DM).</p> <p>Serum from persons with NGT and persons with T2DM was profiled using ProteinChip arrays and time-of-flight mass spectra were generated by surface enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS).</p> <p>Results</p> <p>Mass spectra from NGT- and T2DM-groups were compared. Fifteen proteins ranging from 5 to 79 kDa were differentially expressed (p < 0.05). Five of these proteins showed decreased and ten showed increased serum levels in individuals with T2DM. To be able to identify the proteins, the complexity of the sample was reduced by fractionation approaches. Subsequently, the purified fractions containing biomarkers were separated by one-dimensional SDS-polyacrylamide gel electrophoresis (SDS-PAGE) in two identical lanes. Protein bands of the first lane were excised and subjected to passive elution to recapture the biomarkers on ProteinChip arrays. The corresponding bands of the second lane were subjected to peptide-mass fingerprinting (PMF). Using this approach four of the differentially expressed proteins were identified as apolipoprotein C3 (9.4 kDa), transthyretin (13.9 kDa), albumin (66 kDa) and transferrin (79 kDa). Whereas apolipoprotein C3 and transthyretin were up-regulated, albumin and transferrin were down-regulated in T2DM.</p> <p>Conclusion</p> <p>Protocols for protein profiling by SELDI-TOF MS and protein identification by fractionation, SDS-PAGE and PMF were optimized for serum from humans with T2DM. With these protocols differentially expressed proteins were discovered and identified when serum from NGT- and T2DM-individuals was analyzed.</p>
url http://www.proteomesci.com/content/4/1/22
work_keys_str_mv AT goranssonmichael theuseofproteomicsinidentifyingdifferentiallyexpressedserumproteinsinhumanswithtype2diabetes
AT eberhardsonmichael theuseofproteomicsinidentifyingdifferentiallyexpressedserumproteinsinhumanswithtype2diabetes
AT sundstentea theuseofproteomicsinidentifyingdifferentiallyexpressedserumproteinsinhumanswithtype2diabetes
AT bergstenpeter theuseofproteomicsinidentifyingdifferentiallyexpressedserumproteinsinhumanswithtype2diabetes
AT goranssonmichael useofproteomicsinidentifyingdifferentiallyexpressedserumproteinsinhumanswithtype2diabetes
AT eberhardsonmichael useofproteomicsinidentifyingdifferentiallyexpressedserumproteinsinhumanswithtype2diabetes
AT sundstentea useofproteomicsinidentifyingdifferentiallyexpressedserumproteinsinhumanswithtype2diabetes
AT bergstenpeter useofproteomicsinidentifyingdifferentiallyexpressedserumproteinsinhumanswithtype2diabetes
_version_ 1725194152852848640